Nurse Practitioner Program year 2025 Source: CMS Open Payments, 2026 publication

Erin Vanstory

Nurse Practitioner, Primary Care Coldwater, MS Nurse Practitioner

NPI 1396582508 CMS profile 11578850

431 Central Ave, Coldwater, MS 38618

Open in the dashboard

General payments

$1,586

83 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Vanstory of Coldwater, MS is reported in the CMS Open Payments database as having received $1,586 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $1,586 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Vanstory
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Erin Vanstory were reported at $1,586. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Erin Vanstory Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $0 $139 $44–$421 $149
2023 $0 $163 $53–$481 $160
2024 $0 $176 $54–$511 $164
2025 $1,586 $169 $51–$499 $169

Breakdown

Who paid General payments · program year 2025
  1. AstraZeneca Pharmaceuticals LP $360 14 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $189 11 payments
  3. ITI, Inc. $171 9 payments
  4. Ardelyx, Inc. $168 9 payments
  5. Novo Nordisk Inc $103 5 payments
  6. Janssen Pharmaceuticals, Inc $100 5 payments
  7. AbbVie, Inc. $95 6 payments
  8. GlaxoSmithKline, LLC. $95 5 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $49 3 payments
  10. Phathom Pharmaceuticals, Inc. $43 4 payments
  11. Other $214 12 payments

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $1,586 83 payments
Products named General payments · program year 2025
  1. FARXIGA $296 10 payments
  2. Kerendia $189 11 payments
  3. AIRSUPRA $173 3 payments
  4. CAPLYTA $171 9 payments
  5. IBSRELA $168 9 payments
  6. SPRAVATO $100 5 payments
  7. TRELEGY ELLIPTA $95 5 payments
  8. Ozempic $80 4 payments
  9. UBRELVY $52 3 payments
  10. XIFAXAN $51 3 payments
  11. Other $366 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record